NFE2L2 and diabetes mellitus: Therefore, targeting Nrf2 emerges a therapeutic strategy for revascularization and vascular repair in AAD, namely diabetes, and protecting against cardiovascular stem/progenitor cell exhaustion and aging (Rampin et al., 2022; Wang et al., 2018, 2019).